Nursing homes slam CMS’ proposed staffing level mandate

The latest stories trending on MedCity News.

Editor's Pick

Top Story Nursing Homes Reject CMS' Proposed Staffing Level Requirements CMS released a proposed rule to establish staffing standards among the nation's nursing homes. Reactions have been mixed — but mainly negative. Long-term care facilities say that they can neither find nor afford more workers. On the other hand, some lawmakers argue the proposed rule doesn't do enough to protect care quality for patients. As for labor unions, they seem generally happy with the rule. Sponsored Content Next-Generation Proteomics Presented by Quantum-Si Quantum-Si's Platinum benchtop protein sequencer offers a simpler, more economical alternative to mass spectrometry. Learn More>> We're All Ears If you haven't already, please take 3-5 minutes and tell us what you really think. Your input is valuable and will help us improve MedCity News. As a thank you for your time, you can enter to win a $250 gift card. Tell Us

Featured News

Two Value-Based Care Initiatives That Could Shift the Alternative Payment Model Landscape The Centers for Medicare and Medicaid Services has announced two value-based care alternative payment models set to launch in July 2024, one focused on dementia and one on primary care. Integrating Workers' Comp and Medical Benefits Makes So Much Sense The current dual-system model is inefficient, wasteful, and inconvenient. There is a clear need to integrate workers' comp and medical benefits programs to cut down on costs and alleviate the hassle of dealing with separate care silos. It's possible, and its time has come. Nestlé Sells Peanut Allergy Drug, Ending the Food Giant's Foray Into Biotech Peanut allergy therapy Palforzia, which Nestlé acquired in a multi-billion dollar deal, has been sold to allergy product company Stallergenes Greer. Palforzia was the first FDA-approved drug for peanut allergy, but its sales were hampered by the Covid-19 pandemic. HHS Will Likely Face More Lawsuits Against Drug Price Negotiation Now That It Has Named the First 10 Meds Included In the Plan Novartis became the seventh drugmaker to legally challenge the White House's Medicare drug pricing negotiation program. The company filed its lawsuit three days after HHS announced the first 10 drugs that were selected for the program — its heart failure medication Entresto was one on the list. HHS can expect to face more lawsuits from the manufacturers of the 10 drugs it named last week, experts have warned. Star Therapeutics Lands $90M to Expand Its Drug Discovery Universe Startup Star Therapeutics will use the Series B funding to support clinical development of a drug candidate for von Willebrand disease, a bleeding disorder. The capital will also support the formation of new biotech subsidiaries developing antibodies with therapeutic applications in hematology and immunology.

Resources

MedCity Pivot Podcast: A Conversation With Unlearn.AI CEO About Clinical Trials The founder and CEO of Unlearn.AI seeks to make clinical trials more efficient and less costly by leveraging its Digital Twin technology. If the company is successful, drugs could potentially be brought to market sooner and in a cost effective manner. Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe